Country specific cost comparisons from multinational clinical trials using empirical Bayesian shrinkage estimation: the Canadian ASSENT-3 economic analysis
- 1 April 2005
- journal article
- research article
- Published by Wiley in Health Economics
- Vol. 14 (4) , 327-338
- https://doi.org/10.1002/hec.969
Abstract
The growing number of multinational clinical trials in which patient-level health care resource data are collected have raised the issue of which is the best approach for making inference for individual countries with respect to the between-treatment difference in mean cost. We describe and discuss the relative merits of three approaches. The first uses the random effects pooled estimate from all countries to estimate the difference for any particular country. The second approach estimates the difference using only the data from the specific country in question. Using empirical Bayes estimation a third approach estimates the country-specific difference using a variance-weighted linear sum of the estimates provided by the other two approaches. The approaches are illustrated and compared using the data from the ASSENT-3 trial. Copyright © 2005 John Wiley & Sons, Ltd.Keywords
This publication has 18 references indexed in Scilit:
- Incremental net benefit in randomized clinical trials with quality‐adjusted survivalStatistics in Medicine, 2003
- The Importance of the Normality Assumption in Large Public Health Data SetsAnnual Review of Public Health, 2002
- Assessing and comparing costs: how robust are the bootstrap and methods based on asymptotic normality?Health Economics, 2002
- Incremental net benefit in randomized clinical trialsStatistics in Medicine, 2001
- Linear regression analysis of censored medical costsBiostatistics, 2000
- Economic Evaluation Alongside Multinational Clinical Trials:Study Considerations for GUSTO iibInternational Journal of Technology Assessment in Health Care, 1997
- Confidence intervals for cost-effectiveness ratios: An application of Fieller's theoremHealth Economics, 1996
- Cost Effectiveness of Thrombolytic Therapy with Tissue Plasminogen Activator as Compared with Streptokinase for Acute Myocardial InfarctionNew England Journal of Medicine, 1995
- Economic Analysis in Randomized Control TrialsMedical Care, 1992
- Parametric Empirical Bayes Inference: Theory and ApplicationsJournal of the American Statistical Association, 1983